NIKKEI 225
39,206.07 +401.42 (+1.03%) HANG SENG
18,102.16 +74.45 (+0.41%) CRUDE OIL
81.66 +0.03 (+0.04%) GOLD FUTURES
2,335.80 -8.60 (-0.37%) DOW
39,411.21 +260.91 (+0.67%) Bitcoin GBP
48,059.69 -1,033.55 (-2.11%)
TC Biopharm (Holdings) Plc (TCBPW)
| Previous close | 0.0136 |
| Open | 0.0136 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0136 - 0.0136 |
| 52-week range | 0.0136 - 0.0136 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7540 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireTCBP Announces Launch of Compassionate Use Program for TCB008
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK.
- PR Newswire
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the "ADSs") originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five yea
- PR Newswire
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.
